Dr Dholaria on Ongoing Investigations of Talquetamab and Daratumumab in R/R Multiple Myeloma
August 16th 2023Bhagirathbhai Dholaria, MBBS, discusses next steps for investigating subcutaneous talquetamab and daratumumab in relapsed/refractory multiple myeloma based on data from the phase 1 TRIMM-2 trial.
Read More